Janux Therapeutics Inc
JANX
Get informed when a big investor buys or sells
+ FollowMarket Cap$966.6M
Close$
$-3.72
122.3% downside
Current Fair Value
122.3% downsideOvervalued by 122.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $966.60 Million |
|---|---|
| Enterprise Value | $994.89 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.83 |
| Beta | 2.51 |
| Outstanding Shares | 62,937,295 |
Return
| Return on Equity | -15.80% |
|---|---|
| Return on Assets | -14.55% |
| Return on Invested Capital | -17.67% |
Valuation & Multiples
| P/E Ratio | -9.66 |
|---|---|
| PEG | 27.53 |
| Price to Sales | - |
| Price to Book Ratio | 1.19 |
| Enterprise Value to Revenue | 31.21 |
| Enterprise Value to EBIT | -5.94 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.25
Average shareholder expectationRevenue Estimate
$19.07 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.47
Average shareholder expectationRevenue Estimate
$7.53 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3256▼ 59.18% |
|---|---|
| Total Calls | 30,100▼ 93.31% |
| Total Puts | 9,800▼ 97.63% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 17.85%▼ 77.24% |
|---|---|
| Total Invested | $171.65M▼ 79.26% |
| Investors Holding | 63▼ 137.00% |
ESG Score
No data
About Janux Therapeutics Inc
16 employees